Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (LLY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Eli Lilly And Co Declares Third-Quarter 2012 Dividend; Resumes Share Repurchase Program
Eli Lilly And Co announced that it has declared a dividend for the third quarter of 2012 of $0.49 a share on outstanding common stock. The dividend is payable September 10, 2012 to shareholders of record at the close of business on August 15, 2012. The Lilly Board of Directors has also authorized the resumption of a share repurchase program that was started in 2000, under which the Company has thus far purchased $2.58 billion of shares of a total authorization of $3.0 billion. The Company expects to complete this program by purchasing the remaining $420 million in shares by the end of 2012. The Company also anticipates resuming systematic share repurchases following the completion of the current program. The size and timing of these additional share repurchases will be subject to board approval and will be balanced with other cash flow considerations, including the funding of the Company's dividend, capital expenditures, potential business development opportunities and worldwide macroeconomic conditions. All purchases under the share repurchase program will be made on the open market at prevailing prices. Purchases will be made over a period to be determined by management of the company. Shares acquired will be retired.
Latest Developments for Eli Lilly and Co
- FDA Probes Deaths Of Two Patients On Eli Lilly And Co's Schizophrenia Drug-Reuters
- Eli Lilly And Co Ends Phase II Study Of Investigational Alzheimer's Treatment Amid Abnormal Liver Tests-DJ
- Eli Lilly And Co's PRONOUNCE Study Does Not Achieve Primary Superiority Endpoint For ALIMTA
- Eli Lilly And Co Lymphoma Drug Fails In Late-Stage Trial-Reuters
Latest Key Developments in Pharmaceuticals
- Alk Abello A/S Announces Positive Outcome of Pivotal Phase III Trial with Allergy Immunotherapy Tablet against House Dust Mite Allergy
- EU Fines Ranbaxy Laboratories Ltd And Others For Blocking Cheaper Drugs-Business Standard
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 Million-DJ
- Suheung Capsule Co Ltd to Merge with Subsidiary
- Share this
- Link this
- Digg this


Follow Reuters